您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
OX40/TNFRSF4 His Tag Protein, Human

OX40/TNFRSF4 His Tag Protein, Human

货号: UA010153
价格: 4500
规格: 100μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • Accession

    P43489
  • 表达序列

    Leu29-Ala216, with C-terminal 6*His

    LHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFYNDVVSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASNSSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAHHHHHH

  • 表达宿主

    HEK293
  • 分子量

    28-30kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE&RP-HPLC

  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.

    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.

    · Please avoid repeated freeze-thaw cycles.

  • 稀释度

背景介绍
  • OX40 is a member of the TNF receptor family, which is mainly known to promote effector T cell differentiation, proliferation, long-term survival, and pro-infammatory cytokines production, while inhibiting differentiation and suppressive activity of regulatory T cells (Tregs). It is expressed on activated CD4+ and CD8+ T cells, as well as on other cell types. The OX40 ligand, expressed by antigen presenting cells (APC), activates the OX40 signaling pathway which promotes a robust immune response. The interaction of OX40 with OX40 ligand results in enhanced CD4+ and CD8+ cell proliferation, stimulated cytokine production, and increased survival of antigen specific memory T cell. OX40 expression was revealed as an unfavorable prognostic marker and might be a target for immunotherapy in the future. OX40 was identified as a novel molecule in EC; its elevated expression tends to signify favorable clinical outcomes. As a second immune checkpoint, OX40 may have potential implications for the prognosis and immunomodulation of EC patients. In mice, the absence of OX40 has been shown to cause a strong reduction in the number of effector memory CD4+ cells. Furthermore, the CD8+ response was reduced and tumor growth was accelerated. Accordingly, it is comprehensible that the immune-stimulating properties of OX40 agonists could overcome some of the immunosuppressive properties within tumor environment.

  • 电泳JSON

    • 1μg (R: reducing conditions, N: non-reducing conditions).
  • 反相高效液相色谱JSON(RP-HPLC)

  • ELISA

    • Immobilized OX40/TNFRSF4 His Tag, Human (Cat. No. UA010153) at 2.0μg/mL (100μL/well) can bind Anti-Human OX40 Monoclonal Antibody (Ivuxolimab) with EC50 of 2.03-2.29 ng/mL.